Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Penpulimab in RAIR-DTC
NCT06062563Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anlotinib and penpulimab in differentiated thyroid cancer (DTC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Overall Response Rate at 2 years and Thyroglobulin at 2 years. Status: unknown.
02
Drugs
anlotinibpenpulimab
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT06062563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062563.